Abstract |
A randomized double-blind placebo-controlled trial to determine the efficacy and safety of enoxaparin for the prevention of deep vein thrombosis in patients undergoing elective hip surgery was performed. Prophylaxis, with enoxaparin in a dose of 30 mg subcutaneously twice daily, was begun post-operatively and continued for 14 days. Deep vein thrombosis occurred in 6 (12%) of 50 patients in the enoxaparin group and 21 (42%) of 50 patients in the placebo group (p = 0.0007). Proximal vein thrombosis occurred in two (4%) of the enoxaparin group and 10 (20%) of the placebo group (p = 0.014). Two patients in the placebo group and two in the enoxaparin group developed haemorrhagic complications. This study indicates that fixed-dose enoxaparin begun post-operatively is effective and safe for the prevention of deep vein thrombosis in patients undergoing elective hip replacement.
|
Authors | A G Turpie |
Journal | Acta chirurgica Scandinavica. Supplementum
(Acta Chir Scand Suppl)
Vol. 556
Pg. 103-7
( 1990)
ISSN: 0301-1860 [Print] Sweden |
PMID | 1963014
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Heparin, Low-Molecular-Weight
- Placebos
|
Topics |
- Aged
- Double-Blind Method
- Female
- Heparin, Low-Molecular-Weight
(administration & dosage, therapeutic use)
- Hip Prosthesis
(adverse effects)
- Humans
- Incidence
- Injections, Subcutaneous
- Male
- Ontario
(epidemiology)
- Placebos
- Plethysmography, Impedance
- Postoperative Complications
(epidemiology, prevention & control)
- Thrombophlebitis
(epidemiology, prevention & control)
|